Lilly NCDs Partnership

Partnership Objectives

  1. Lead effective pilots of new comprehensive approaches to strengthen diabetes care.
  2. Advocate proven methods to governments for better disease management.
  3. Increase appropriate use of and compliance with medicines to improve outcomes.

The Partnership aims to have a positive impact in four high-prevalence countries: Brazil, India, Mexico and South Africa. The Partnership aims to have a positive impact in four high-prevalence countries: Brazil, India, Mexico and South Africa. Copyright Lilly

What are the health needs and challenges

Nearly a century ago, Lilly made a promise to make life better for people with diabetes. Remaining true to this promise, in 2011 they started the diabetes-focused Lilly NCD Partnership to help people at risk, healthcare workers, and governments better understand and manage diabetes.

While non-communicable diseases (NCDs) - like diabetes, heart disease and cancer - impact individuals and societies around the world, their impact is particularly devastating in low- and middle-income countries that are poorly equipped to act. Reported cases of diabetes have more than doubled in the past three decades: 347 million people worldwide have diabetes, up from 153 million in 1980, and this figure is projected to rise to 472 million by 2030 — 80% of these cases will be in low- and middle-income countries.

Description of partnership activities and how they address needs and challenges

To improve health outcomes, Lilly works with partners using a novel operational framework: Research, Report and Advocate.

  • Research: pilot new approaches to improve access to care and collect rigorous outcomes data;
  • Report: transparently share data about what works and what doesn’t with governments, health experts, and others working in global health;
  • Advocate: use evidence from our pilot projects to advocate for scale up of proven, cost-effective solutions for maximum benefit to people.

These NCD projects currently run in Brazil, India, Mexico and South Africa:


Type 2 diabetes and gestational diabetes are significant and increasing health challenges in Brazil. Lilly’s aim is to reduce the incidence of Type 2 diabetes in women previously diagnosed with gestational diabetes and to improve skills for healthcare workers caring for people at risk of Type 1 diabetes especially in rural and underserved areas.

The NCD partnership does this in two ways. First by evaluating the effectiveness of an intensive lifestyle change program to prevent or delay development of Type 2 diabetes in women who previously had gestational diabetes. Secondly, through developed Type 1 diabetes educational tools based on the experience and methodology used by Instituto da Criança com Diabetes (ICD).


The projected number of people in India with diabetes and hypertension is rising quickly while detection rates of diabetes and high blood pressure remain low. India is second only to China in the total number of cases.

The Lilly NCD partnership works to integrate diabetes prevention services, diabetes and hypertension community-based care, and improve diabetes self-management. Interventions include mapping local health conditions, community awareness, use of electronic tools, and training of health workers.


With a high Type 2 diabetes prevalence and a majority of cases managed only by medical specialists, there is a strong need for greater diabetes prevention and treatment in primary care settings. To achieve this, the government is rolling out the Casalud model of care to enable Type 2 diabetes management at the primary care level. Lilly’s partnership is conducting rigorous evaluation of the Casalud model to enable continual improvement and strengthening. This will enable improved access to effective and appropriate care for diabetes throughout the primary care clinic network which covers 50 percent of Mexico’s population.

South Africa

South Africa has one of the highest rates of obesity in Africa while Type 2 diabetes is rising dramatically in both urban and rural settings. To improve quality of life of people at risk, the Lilly NCD partnership works to increase access to diabetes prevention services, to integrate diabetes and hypertension primary care services, and to improve diabetes self-management.

Through the NCD partnership, Lilly does this by training community-based health workers to diagnose and refer patients , launching peer support groups to raise awareness about diabetes, and strengthening clinic capabilities. Lilly is also leveraging current HIV/AIDS treatment capabilities and applying these learnings to a diabetes care model.


Lilly Non-Communicable Disease Partnership

Lilly Collaborates to Fight NCDs in South Africa

Partnership information

Company(ies) Eli Lilly and Company

Partner(s) Carlos Slim Health Institute, Donald Woods Foundation, Instituto da Criança Com Diabetes, Population Services International (PSI), Project HOPE, Public Health Foundation of India, Universidade Federal do Rio Grande do Sul

Type of Partner(s) Academia / Hospitals, NGOs

Therapeutic Focus Non-Communicable Diseases

Disease(s) Diabetes

Program Type(s) Health System Infrastructure - Development of Physical Infrastructure, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Targeted Population(s) Children, Men, Patients in needs of treatment, People with low income, Women

Region(s) Latin America & Caribbean, South Asia, Sub-Saharan Africa

Number of Countries 4

Country(ies) Brazil, India, Mexico, South Africa

Start Date 2012

More information Lilly NCD Partnership

Anticipated completion date 2016